Is SLDB or SLNO more undervalued in 2026?

CirclFi compares Solid Biosciences Inc. (SLDB) and Soleno Therapeutics, Inc. (SLNO) using 13 institutional-grade valuation models. SLDB has a Quality of Company score of 4.4/10 while SLNO scores 7.1/10.

Which is a better buy — SLDB or SLNO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SLDB and SLNO valuations compare?

SLDB at $7.07 and SLNO at $53.01 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SLDB vs SLNO Valuation Comparison 2026 — Intrinsic Value Analysis

SLDB

Biotechnology

Solid Biosciences Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$7.07

Last close

Models

7/13

Active

SLNO

Biotechnology

Soleno Therapeutics, Inc.

Quality

7.1

out of 10

Value Trap

SAFE

Price

$53.01

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	SLDB Fair Value	SLDB Upside	SLNO Fair Value	SLNO Upside
Bayesian DCF	Intrinsic	$3.47	-50.9%	$13.39	-74.7%
Earnings Power Value	Intrinsic	—	—	$2.73	-94.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$4.75	-32.9%	$6.44	-87.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SLDB vs SLNO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SLDB vs SLNO — Which Stock Is More Undervalued?

SLNO scores higher with a 7.1/10 quality rating vs SLDB's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Solid Biosciences Inc. (SLDB) and Soleno Therapeutics, Inc. (SLNO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SLDB currently trades at $7.07 with a QOC of 4.4/10, while SLNO trades at $53.01 with a QOC of 7.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).